#Germany #Implantica #RefluxStop™ #GERD #Magdeburg

Implantica's Strategic Expansion of RefluxStop™

Implantica AG, a pioneering medtech company, continues its mission to innovate healthcare solutions by expanding its RefluxStop™ program. This time, the company is making headlines with its collaboration with the renowned Universitätsklinik Magdeburg in Germany, a key player in the treatment of gastroesophageal reflux disease (GERD). This strategic partnership marks a significant milestone for the company, which aims to improve the lives of the one billion people suffering from acid reflux worldwide.

The Significance of the Partnership

On December 19, 2024, Implantica announced that the Universitätsklinik Magdeburg performed its first RefluxStop™ procedures led by esteemed professionals, Professor Dr. med. Frank Benedix and Dr. med. Steffi Peglow. This university hospital, boasting over 25 specialized departments, provides comprehensive consultations for reflux disease, thus enhancing the quality of care available to patients.

As a facility that reports directly to the INEK, the hospital's inclusion in the RefluxStop™ initiative plays a crucial role in the future reimbursement landscape for GERD treatments in Germany. With many more hospitals in the pipeline for this innovative procedure, Implantica is poised to expand its reach further within the healthcare system.

What is RefluxStop™?

RefluxStop™ is a revolutionary device designed to tackle the root causes of acid reflux without the need to encircle the esophagus—a common issue with traditional surgeries that often lead to pain and swallowing difficulties. Instead, it cleverly restores the natural position of the lower esophageal sphincter, promoting a healthier physiological barrier to reflux. This innovative approach has already demonstrated promising long-term results across Europe, with over 1,000 patients benefitting from the surgery.

Professor Benedix expresses his enthusiasm for bringing such cutting-edge technology to his patients, stating, “We are excited to offer the latest innovative technology in surgical treatment for GERD. Many patients who struggled with the debilitating symptoms of acid reflux will now have access to effective solutions.”

Economic Impact

The impact of GERD extends beyond individual patients; it poses a substantial socio-economic challenge. Dr. Peter Forsell, CEO of Implantica, highlights that approximately 17% of the German population suffers from GERD, resulting in significant work absences and economic losses—estimated to exceed €600 million annually. Such statistics underscore the importance of innovative treatments like RefluxStop™ in alleviating patient suffering and reducing healthcare costs long-term.

“Providing advanced solutions like RefluxStop™ is not just about enhancing patient care; it's about addressing the socio-economic ramifications of untreated GERD on society,” says Dr. Forsell.

Looking Ahead

With the backing of Universitätsklinik Magdeburg, Implantica is set on a trajectory of significant growth and innovation in the realm of reflux treatment. The company is not only dedicated to improving patient outcomes but also aims to shape the future of healthcare with its patented technologies that enable remote health monitoring and wireless energy for implants.

As RefluxStop™ gathers momentum, more partnerships and clinical engagements are expected, creating a ripple effect that could change the landscape of GERD treatments on an international scale.

For more updates and detailed information about Implantica and its initiatives, visit Implantica's official website.